Clinical Trials Directory

Trials / Completed

CompletedNCT01720576

Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
60 (actual)
Sponsor
Regeneron Pharmaceuticals · Industry
Sex
All
Age
60 Years
Healthy volunteers
Accepted

Summary

This is a study to assess the safety and tolerability of subcutaneously administered REGN1033 (SAR391786) in healthy volunteers.

Conditions

Interventions

TypeNameDescription
DRUGREGN1033 (SAR391786)
DRUGPlacebo

Timeline

Start date
2012-10-01
Primary completion
2013-06-01
Completion
2013-06-01
First posted
2012-11-02
Last updated
2013-09-12

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01720576. Inclusion in this directory is not an endorsement.